立体定向体部放疗推量治疗中危前列腺癌:一项1期剂量递增研究
这项1期剂量递增试验将30例中危前列腺癌患者纳入3个单次立体定向体部放疗推量剂量组(10 Gy、12.5 Gy、15 Gy),随后补充放疗37.5 Gy/15次。中位随访72个月,15 Gy组2例出现晚期≥3级胃肠及泌尿生殖毒性,其中1例在直肠溃疡反复活检后发生4级直肠瘘;高剂量组中位PSA最低值及达到PSA最低值<0.2 ng/mL的比例改善。作者认为除该4级毒性外,单次立体定向体部放疗推量可行且耐受良好,需更大规模研究。
要点
- 30例中危前列腺癌患者分3组接受单次立体定向体部放疗推量10 Gy、12.5 Gy、15 Gy,随后补充放疗37.5 Gy/15次。
- 15 Gy组2例出现晚期≥3级胃肠及泌尿生殖毒性,其中1例在直肠溃疡反复活检后发生4级直肠瘘。
- 中位PSA最低值10 Gy组0.4 ng/mL、12.5 Gy组0.09 ng/mL、15 Gy组0.07 ng/mL,高剂量组4年PSA及最低值<0.2 ng/mL比例显著改善。
核心结论
- 除1例4级毒性(可能部分归因于直肠溃疡反复活检)外,单次立体定向体部放疗推量可行且耐受良好,作者认为需更大规模研究以更好记录该方案结局。
研究设计与样本
- 1期剂量递增试验,纳入中危前列腺癌患者30例,分3个单次立体定向体部放疗剂量组(10 Gy、12.5 Gy、15 Gy),每组10例。
- 所有患者随后接受补充放疗37.5 Gy/15次,植入3枚金标用于影像引导,模拟及治疗时使用导尿管和直肠内球囊,采用T2磁共振成像勾画靶区、电影磁共振成像计算患者特异性内靶区边界。
主要发现
- 中位随访72个月,60%患者为不利中危前列腺癌,2例出现生化失败。
- 15 Gy组2例发生晚期≥3级胃肠及泌尿生殖毒性,其中1例在直肠溃疡反复活检后发生4级直肠瘘。
- 中位PSA最低值10 Gy组0.4 ng/mL、12.5 Gy组0.09 ng/mL、15 Gy组0.07 ng/mL;随剂量升高,4年PSA及达到PSA最低值<0.2 ng/mL的比例显著改善。
- 各领域生活质量较基线无显著变化,3组间最小临床重要变化无统计学差异。
关键数值与推荐
- 单次立体定向体部放疗推量剂量水平:10 Gy、12.5 Gy、15 Gy;补充放疗37.5 Gy/15次。
- 毒性采用不良事件通用术语标准v3.0评估,生活质量采用扩展前列腺癌指数综合量表评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文报告1例4级毒性,可能部分归因于直肠溃疡反复活检。
- 作者认为需更大规模研究以更好记录该方案结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-dose-rate brachytherapy boost plus external beam radiation therapy is an established option for intermediate-risk prostate cancer (PCa). Stereotactic body radiation therapy (SBRT) boost can potentially mimic high-dose-rate boost and could be a viable alternative. Here we report the long-term outcomes of a phase 1 dose-escalation trial of single-fraction SBRT boost. METHODS AND MATERIALS: Patients had intermediate-risk PCa and were accrued to 3 different SBRT single-fraction dose-level cohorts (10 Gy, 12.5 Gy, and 15 Gy). All received supplemental radiation therapy afterwards (37.5 Gy in 15 fractions). Three gold fiducials were implanted for image guidance. Patients were simulated and treated with a foley catheter and intrarectal balloon. A T2 magnetic resonance imaging scan was used for contouring, and a cine magnetic resonance imaging scan was used to calculate patient-specific internal target volume margins. Toxicity and quality-of-life data were collected using Common Terminology Criteria for Adverse Events v3.0 and the Expanded Prostate Cancer Index Composite. RESULTS: 30 patients were accrued, 10 in each cohort. Median follow-up was 72 months. 60% had unfavorable intermediate-risk PCa. Two patients in the 15 Gy cohort developed late grade ≥3 gastrointestinal and genitourinary toxicity, with 1 patient suffering from a grade-4 rectal fistula after a rectal ulcer was biopsied repeatedly. Two patients had biochemical failure. Median PSA nadir was 0.4 ng/mL with 10 Gy, 0.09 ng/mL with 12.5 Gy and 0.07 ng/mL with 15 Gy. Median PSA at 4 years as well as proportion achieving a nadir <0.2 ng/mL improved significantly with higher doses. There was no significant change in quality of life from baseline in any of the domains, and the minimal clinically important change was not statistically different between the 3 cohorts. CONCLUSIONS: Other than a grade 4 toxicity, which may in part be due to repeated biopsies of a rectal ulcer, single-fraction SBRT boost was feasible and well tolerated. Larger studies are warranted to better document the outcomes of such an approach.
引用
- Alayed Y, Loblaw A, Chu W, et al. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study. Int J Radiat Oncol Biol Phys. 2019. PMID: 31002941. doi:10.1016/j.ijrobp.2019.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。